

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/701,041	11/04/2003	Benjamin Oshlack	200.1133CON2	6154
DAVIDSON DA		EXAMINER		
DAVIDSON, DAVIDSON & KAPPEL, LLC 14th Floor 485 Seventh Avenue New York, NY 10018			ALSTRUM ACEVEDO. JAMES HENRY	
			ART UNIT	PAPER NUMBER
			1616	
SHORTENED STATUTORY I	PERIOD OF RESPONSE	MAIL DATE	DELIVER	Y MODE
31 DAY		03/27/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)				
Office Action Summary		10/701,041	OSHLACK ET AL.				
		Examiner	Art Unit				
		James H. Alstrum-Acevedo	1616				
Period fo	The MAILING DATE of this communication a r Reply	appears on the cover sheet wit	h the correspondence address				
WHIC - Exter after - If NO - Failu Any r	CRTENED STATUTORY PERIOD FOR REICHEVER IS LONGER, FROM THE MAILING asions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by state ply received by the Office later than three months after the material part of the m	DATE OF THIS COMMUNIC 1.136(a). In no event, however, may a re od will apply and will expire SIX (6) MONT tute, cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).				
Status							
1)🛛	Responsive to communication(s) filed on 04	November 2003					
′=		his action is non-final.	•				
,							
٠,۵	closed in accordance with the practice under	•					
Dispositi	on of Claims						
4)⊠	4)⊠ Claim(s) <u>62-73</u> is/are pending in the application.						
-	4a) Of the above claim(s) is/are withdrawn from consideration.						
	Claim(s) is/are allowed.						
7)	Claim(s) is/are objected to.						
,	Claim(s) <u>62-73</u> are subject to restriction and	I/or election requirement.					
·	on Papers	·					
	The specification is objected to by the Exam	iner					
• —	The drawing(s) filed on is/are: a) a		by the Examiner				
10,	Applicant may not request that any objection to t	· · · · · · · · · · · · · · · · · · ·					
	Replacement drawing sheet(s) including the con-						
11)	The oath or declaration is objected to by the	·					
•	ınder 35 U.S.C. § 119		•				
12)	Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. §	119(a)-(d) or (f).				
a)	All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority docume	ents have been received in Ap	oplication No				
	3. Copies of the certified copies of the p	riority documents have been	received in this National Stage				
	application from the International Bur	• • • • • • • • • • • • • • • • • • • •					
* 5	See the attached detailed Office action for a	list of the certified copies not r	eceived.				
Attachmen	t(s)						
	e of References Cited (PTO-892)		ummary (PTO-413)				
	e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08))/Mail Date formal Patent Application				
	rr No(s)/Mail Date	6) Other:					

DETAILED ACTION

Claims 62-73 are pending. Applicants cancelled claims 1-61.

Election/Restrictions

This application contains claims directed to the following patentably distinct species: opioid antagonist. The species are independent or distinct because these species represent compounds having a great diversity of chemically different core structures and biological activities in addition to the required opioid antagonist activity (e.g. some opiates are characterized by sedating effects, such as fentanyl).

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 62, 65, and 69 are generic. A proper response would clearly elect a single opioid antagonist from the list of opioid antagonists recited in claims 63, 66, or 70-72, which would be identified by chemical name, common name, chemical structure, and/or any trademarked names associated with said opioid antagonist that are known to Applicants.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an

allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

A telephone call was made to Mr. Robert J. Paradiso on March 19, 2007 at \sim 4:20 pm EST to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/701;041

Art Unit: 1616

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to James H. Alstrum-Acevedo whose telephone number is (571)

272-5548. The examiner can normally be reached on M-F, 9:00-6:30, with every other Friday

off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

James H. Alstrum-Acevedo, Ph.D.

Patent Examiner

Technology Center 1600

Johann Richter, Ph. D., Esq. Supervisory Patent Examiner

Page 4

Technology Center 1600